Gabriel Brooks insider trades: Solid Biosciences (SLDB) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Gabriel reports to the SEC
Open-market buys and sales
6 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | SLDB | ↓ Sell | 4,374 | $5.62 | $25K | Direct | Oct 20, 2026 (1d) |
| Feb 4, 2026 | SLDB | ↓ Sell | 12,616 | $6.44 | $81K | Direct | Feb 6, 2026 (2d) |
| Feb 2, 2026 | SLDB | ↓ Sell | 28,335 | $6.44 | $182K | Direct | Feb 2, 2026 (0d) |
| Oct 20, 2025 | SLDB | ↓ Sell | 2,895 | $5.96 | $17K | Direct | Oct 21, 2025 (1d) |
| Feb 14, 2025 | SLDB | ↓ Sell | 3,256 | $3.96 | $13K | Direct | Feb 18, 2025 (4d) |
| Oct 21, 2024 | SLDB | ↓ Sell | 2,923 | $6.50 | $19K | Direct | Oct 22, 2024 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other SLDB insiders
Open-market trades in the last 12 months
About Gabriel Brooks's insider trades
Gabriel Brooks is Chief Medical Officer at Solid Biosciences (SLDB). Since Oct 21, 2024, Gabriel has reported no open-market purchases and 6 sales worth $337K on SEC Form 4. In the last 12 months: 3 sales ($288K).
Their filings also include option exercises (6 filings), grants and awards (5 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SLDB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.